Halozyme Financial Statements (HALO)
|
|
|
|
Report date
|
|
|
22.02.2022 |
21.02.2023 |
20.02.2024 |
18.02.2025 |
17.02.2026 |
|
11.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
443.3 |
660.1 |
829.3 |
1 015 |
1 397 |
|
1 508 |
|
Operating Income, bln rub |
|
|
275.9 |
267.5 |
337.6 |
551.5 |
816.3 |
|
859.3 |
|
EBITDA, bln rub |
? |
|
259.0 |
315.5 |
451.9 |
656.5 |
904.3 |
|
960.6 |
|
Net profit, bln rub |
? |
|
402.7 |
202.1 |
281.6 |
444.1 |
316.9 |
|
348.8 |
|
|
OCF, bln rub |
? |
|
299.4 |
240.1 |
388.6 |
479.1 |
651.6 |
|
677.4 |
|
CAPEX, bln rub |
? |
|
1.46 |
4.81 |
15.3 |
10.7 |
6.97 |
|
9.76 |
|
FCF, bln rub |
? |
|
298.0 |
235.3 |
373.3 |
468.4 |
644.6 |
|
667.7 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
86.0 |
253.3 |
299.3 |
304.4 |
274.9 |
|
301.2 |
|
Cost of production, bln rub |
|
|
81.4 |
139.3 |
192.4 |
159.4 |
305.4 |
|
348.0 |
|
R&D, bln rub |
|
|
35.7 |
66.6 |
76.4 |
79.0 |
81.5 |
|
92.3 |
|
Interest expenses, bln rub |
|
|
7.53 |
16.9 |
18.8 |
18.1 |
18.1 |
|
19.1 |
|
|
Assets, bln rub |
|
|
1 104 |
1 842 |
1 733 |
2 063 |
2 525 |
|
2 673 |
|
Net Assets, bln rub |
? |
|
197.0 |
169.8 |
83.8 |
363.8 |
48.8 |
|
219.6 |
|
Debt, bln rub |
|
|
876.7 |
1 506 |
1 499 |
1 506 |
2 143 |
|
2 145 |
|
Cash, bln rub |
|
|
740.9 |
362.8 |
336.0 |
596.1 |
142.8 |
|
318.6 |
|
Net debt, bln rub |
|
|
135.8 |
1 143 |
1 163 |
909.7 |
2 000 |
|
1 826 |
|
|
Ordinary share price, rub |
|
|
40.2 |
|
|
47.8 |
67.3 |
|
68.3 |
|
Number of ordinary shares, mln |
|
|
140.6 |
136.8 |
131.9 |
126.8 |
119.8 |
|
118.1 |
|
|
Market cap, bln rub |
|
|
5 655 |
0 |
0 |
6 064 |
8 065 |
|
8 072 |
|
EV, bln rub |
? |
|
5 791 |
1 143 |
1 163 |
6 973 |
10 065 |
|
9 898 |
|
Book value, bln rub |
|
|
197 |
-786 |
-806 |
-455 |
-1 513 |
|
-1 315 |
|
|
EPS, rub |
? |
|
2.86 |
1.48 |
2.13 |
3.50 |
2.64 |
|
2.95 |
|
FCF/share, rub |
|
|
2.12 |
1.72 |
2.83 |
3.69 |
5.38 |
|
5.65 |
|
BV/share, rub |
|
|
1.40 |
-5.74 |
-6.11 |
-3.59 |
-12.6 |
|
-11.1 |
|
|
EBITDA margin, % |
? |
|
58.4% |
47.8% |
54.5% |
64.7% |
64.8% |
|
63.7% |
|
Net margin, % |
? |
|
90.8% |
30.6% |
34.0% |
43.7% |
22.7% |
|
23.1% |
|
FCF yield, % |
? |
|
5.27% |
|
|
7.72% |
7.99% |
|
8.27% |
|
ROE, % |
? |
|
204.5% |
119.0% |
336.0% |
122.1% |
649.2% |
|
158.8% |
|
ROA, % |
? |
|
36.5% |
11.0% |
16.2% |
21.5% |
12.5% |
|
13.1% |
|
|
P/E |
? |
|
14.0 |
0.00 |
0.00 |
13.7 |
25.5 |
|
23.1 |
|
P/FCF |
|
|
19.0 |
0.00 |
0.00 |
12.9 |
12.5 |
|
12.1 |
|
P/S |
? |
|
12.8 |
0.00 |
0.00 |
5.97 |
5.77 |
|
5.35 |
|
P/BV |
? |
|
28.7 |
0.00 |
0.00 |
-13.3 |
-5.33 |
|
-6.14 |
|
EV/EBITDA |
? |
|
22.4 |
3.62 |
2.57 |
10.6 |
11.1 |
|
10.3 |
|
Debt/EBITDA |
|
|
0.52 |
3.62 |
2.57 |
1.39 |
2.21 |
|
1.90 |
|
|
R&D/CAPEX, % |
|
|
2 448% |
1 385% |
499.3% |
739.0% |
1 169% |
|
945.1% |
|
|
CAPEX/Revenue, % |
|
|
0.33% |
0.73% |
1.84% |
1.05% |
0.50% |
|
0.65% |
|
| Halozyme shareholders |
